CurrentUnitedHealthcarePolicy CS379NM.B

Respiratory Pathogen Nucleic Acid Nm Cs

State-specific UnitedHealthcare medical policy (New Mexico) governing coverage of respiratory pathogen nucleic acid detection testing, with emphasis that outpatient multiplex panels of six or more targets are considered unproven and not medically necessary. Includes applicable CPT/HCPCS proprietary codes and clinical evidence review.

Policy Summary

PayerUnitedHealthcare

PolicyRespiratory Pathogen Nucleic Acid Nm Cs

Policy CodePolicy CS379NM.B

Change TypeRevised

Effective DateMay 1, 2026

Next Review Date

Key ActionThis medical policy applies only to the state of New Mexico; providers must reference member-specific benefit plan documents and applicable federal/state contractual requirements when deciding coverage.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

>=6Panel target count threshold for outpatient not medically necessary

9,414Participants in Liu et al. mNGS meta-analysis

360Participants in Meltzer randomized trial

Coverage Summary

This is a New Mexico–specific UnitedHealthcare medical policy (Policy Number CS379NM.B) addressing coverage of respiratory pathogen nucleic acid detection testing. The policy applies only to the state of New Mexico and includes applicable CPT/HCPCS and proprietary panel codes for reference.

Policy statement: Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary. Effective date: 2026-05-01. Last review: 2026-05-01.

Conclusion: Evidence is insufficient to support outpatient use of respiratory pathogen panels of six or more targets; evidence quality is low and heterogeneous. Metagenomic NGS shows promising diagnostic accuracy in pooled analyses, but clinical utility in outpatients remains unproven. Therefore, outpatient multiplex panels with >=6 targets are considered unproven/not medically necessary.

Medical-Necessity Criteria

Coverage Rationale / Medical Necessity

Policy statement:

Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary due to insufficient evidence of efficacy for all indications

This is the core coverage determination for outpatient settings in New Mexico.

Not Medically Necessary — Outpatient Multiplex Panels

Determination for outpatient settings: Respiratory pathogen panels with >=6 targets are considered unproven and not medically necessary in the outpatient setting due to insufficient evidence of clinical utility. Rationale: larger fixed multiplex panels include diverse pathogens unlikely to be tested simultaneously in outpatients, detection may reflect prolonged shedding or colonization rather than active infection, results can yield multiple positives or coinfections complicating interpretation, and the available studies are low quality, heterogeneous, and lack consistent patient‑outcome improvements.

Threshold

Outpatient multiplex respiratory panels with >= 6 targets — Not medically necessary>= 6 targets

Coding

Proprietary panel codes referencedHCPCS

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including SARS-CoV-2, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.

CPT codes for multiplex respiratory virus NAATCPT

87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, multiple types or subtypes, 12-25 targets.

Provider Actions

Documentation Required

Reference state-specific application

This medical policy applies only to the state of New Mexico; providers must reference member-specific benefit plan documents and applicable federal/state contractual requirements when deciding coverage.

This policy applies only to New Mexico; check member-specific benefits and applicable federal or state contractual requirements before determining coverage.

Billing Rule

Code use and reference

Providers may report the listed CPT/HCPCS codes for respiratory pathogen nucleic acid testing; inclusion of a code in the policy does not guarantee coverage—benefit plan and state/federal requirements govern.

0115U
0202U
0223U
0225U
0556U
0563U
0564U
87632
87633
Inclusion of a code in this policy is for reference only and does not guarantee coverage or reimbursement; member-specific benefit plans and applicable laws govern.

Background and Definitions

Background: Molecular assays (RT‑PCR and other NAATs, and metagenomic NGS) detect microbial nucleic acids in respiratory specimens, but detection does not confirm a viable organism or ongoing replication. Larger fixed multiplex panels test a predefined, diverse set of pathogens simultaneously, raising clinical utility concerns in outpatients because of issues such as prolonged shedding, multiple positive results/coinfections, and variable accuracy across targets.

Term	Definition
mNGS	Metagenomic next-generation sequencing, comprehensive detection of genetic material from all organisms in a specimen.
Multiplex PCR panel	A nucleic acid amplification test that simultaneously tests a predefined set of microbial targets.

Key evidence metrics:

- Conclusion: Insufficient evidence supports outpatient use of respiratory pathogen panels of six or more targets; evidence quality is low or heterogeneous.

- mNGS pooled AUC (all studies): 0.88 (95% CI, 0.85–0.90).

- mNGS pulmonary subgroup pooled sensitivity: 0.90 (95% CI, 0.77–0.96); specificity: 0.79 (95% CI, 0.58–0.91).

- Participant counts: Liu et al. meta‑analysis included 9,414 individuals; Meltzer randomized trial enrolled 360 participants (urgent care RCT).

Revision History

2026-05-01revisedLatest

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information. Added reference link to the Reimbursement Policy titled Laboratory Services Policy, Professional; archived previous policy version CS379NM.A.